Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Increasing body mass index influences response to treatment with dexlansoprazole or lansoprazole

A study published ahead of print the Alimentary Pharmacology & Therapeutics examines the effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.

News image

Higher body mass index is a recognised risk factor for gastro-esophageal reflux disease (GERD).

Data regarding the impact of body mass index on proton pump inhibitor therapy are conflicting.

Dr Peura and colleagues assessed the impact of body mass index on baseline heartburn symptom severity and frequency and response to proton pump inhibitor therapy in patients with non-erosive gastro-esophageal reflux disease or erosive esophagitis.

In post hoc analyses of phase 3 trial data, 621 gastro-esophageal reflux disease and 2692 erosive esophagitis patients were stratified by body mass index.

The researchers noted that gastro-esophageal reflux disease patients received either dexlansoprazole MR 30 mg or placebo daily for 4 weeks.

Erosive esophagitis patients received either dexlansoprazole MR 60 mg or lansoprazole 30 mg for 8 weeks.

The team of doctors assessed the symptom frequency and severity at baseline and subsequently by daily diary.

PPI reduction in symptoms were similar across body mass index categories
Alimentary Pharmacology & Therapeutics

In both the gastro-esophageal reflux disease and erosive esophagitis cohorts, baseline heartburn severity increased with increasing body mass index.

The impact of proton pump inhibitor therapy on the reduction in heartburn symptom frequency and severity in both gastro-esophageal reflux disease and erosive esophagitis patients was similar across body mass index categories.

The researchers found that erosive esophagitis healing rates in patients treated with dexlansoprazole but not lansoprazole were higher in obese patients compared with those with a body mass index 30 kg/m2.

Differences between the proton pump inhibitor were small.

Dr Peura's team concluded, "The proton pump inhibitor evaluated in this study reduced the frequency and severity of 24-hour heartburn regardless of baseline body mass index."

"In addition, because patients with higher body mass index have more severe symptoms at baseline, they may experience greater therapeutic gain with dexlansoprazole and possibly lansoprazole treatment."

Aliment Pharmacol Ther 2013: DOI: 10.1111/apt.12270
13 March 2013

Go to top of page Email this page Email this page to a colleague

 29 May 2015

Advanced search
 29 May 2015 
Comfort during colonoscopy
 29 May 2015 
Colorectal neoplasia in liver transplant candidates
 29 May 2015 
Cervical cancer with immunosuppressive therapy in IBD
 28 May 2015 
Excercise and IBD
 28 May 2015 
Probiotics and Crohn's disease
 28 May 2015 
Bleeding and colorectal endoscopic submucosal dissection
 27 May 2015 
Vegetables and fruit and IBD
 27 May 2015 
Radiofrequency ablation for treatment of GERD
 27 May 2015 
Management of constipation and IBS
 26 May 2015 
Antimicrobials for intraabdominal infection
 26 May 2015 
Calcium channel blockers and GI bleeds
 26 May 2015 

Risk factors for celiac disease

 25 May 2015 
Colorectal cancer screening
 25 May 2015 
Saccharomyces boulardii and H. pylori
 25 May 2015 
Risk of GI bleeds with NSAIDs
 22 May 2015 
Colonoscopy screening for colorectal cancer
 22 May 2015 
Treatment with anti-integrin antibodies in IBD
 22 May 2015 
Care of patients with GERD
 21 May 2015 
Lymphoma in IBD
 21 May 2015 
Serrated polyps and colorectal cancer
 21 May 2015 
Imaging for hepatocellular carcinoma
 20 May 2015 
Pancreatic neuroendocrine tumors
 20 May 2015 
Surveillance in long-segment Barrett's
 20 May 2015 
Refractory metastatic colorectal cancer
 19 May 2015 
Metabolic syndrome and Barrett's
 19 May 2015 
PPIs and cryptogenic liver abscess
 19 May 2015 
Anti-integrin antibodies in IBD
 18 May 2015 
ESPGHAN celiac guidelines
 18 May 2015 
HLA haplotypes and primary sclerosing cholangitis
 18 May 2015 
Safety of PPI
 15 May 2015 
Microscopic colitis risk with PPIs/NSAIDs
 15 May 2015 
Management of nonhospitalized ulcerative colitis
 15 May 2015 
Diabetes and infections in IBD with immunomodulation
 14 May 2015 
Diagnosis of spontaneous bacterial peritonitis
 14 May 2015 
Mortality in US patients with cirrhosis
 14 May 2015 
Radiation exposure during ERCP
 13 May 2015 
Predictors of IBD
 13 May 2015 
Psychological distress and liver disease mortality
 13 May 2015 
Hypnotherapy in IBS/IBD
 12 May 2015 
Bleeding in NSAID users with H.pylori
 12 May 2015 
Capsule colonoscopy detects colorectal polyps
 12 May 2015 
Anti-TNF biologics in acute severe ulcerative colitis
 11 May 2015 
Management of Barrett's esophagus
 11 May 2015 
Marker to detect recurrence of Crohn's
 11 May 2015 
Thalidomide for IBD
 08 May 2015 
Surveillance colonoscopy in colorectal cancer
 08 May 2015 
HCV treatment with compensated cirrhosis
 08 May 2015 
Medical management of Crohn's
 07 May 2015 
Surgical complications in ulcerative colitis
 07 May 2015 
Combination therapy for noncirrhostic patients
 07 May 2015 
Anxiety and new-onset dyspepsia
 06 May 2015 
PPIs and spontaneous bacterial peritonitis
 06 May 2015 
Infant feeding and celiac disease
 06 May 2015 
Preventing recurrent C. diff infection
 05 May 2015 
Fatigue in primary sclerosing cholangitis
 05 May 2015 
Annual CT scans after esophagectomy for cancer
 05 May 2015 
Prevalence of eosinophilic esophagitis
 04 May 2015 
Stress resilience and peptic ulcer disease
 04 May 2015 
Endoscope storage and microbial colonization
 04 May 2015 
Menarche and NAFLD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us